[Clinical assessment of therapeutic results of Ergolactyn (bromocriptine) in Parkinson's disease].
The effect of Ergolaktyna (bromocriptine) produced by Grodzisk Pharmaceutical Works POLFA on the intensity of parkinsonism manifestations was studied in 27 patients in four clinical centres. All patients had moderately advanced parkinsonism and prior to Ergolaktyna they received L-Dopa preparations which were also given concomitantly with that preparation. The final assessment was done after 4 months of treatment in 18 cases. A good effect of the drug was found in 55% of cases (reduction of the intensity of parkinsonian signs, increased fitness and life activity). Adverse effects developed in 4 cases and required drug withdrawal.